NIAID plays a leading role in the discovery, development, and characterization of new vaccine adjuvants that may be used to: improve the efficacy of current vaccines; design new or improved vaccines for existing and emerging infectious diseases; and develop vaccines to treat allergies, autoimmune diseases, and cancer.
Discovery and Mechanistic Research
Discovery and Mechanistic Research seeks to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines and elucidate the immune mechanism of novel receptors.
Adjuvant Comparison programs support the side-by-side comparison of experimental vaccines formulated with different adjuvants, to include comprehensive assessments of the strength, quality, breadth, and durability of immune responses.
Adjuvant Development supports the preclinical development of novel adjuvants for use in vaccines targeting immune-mediated or infectious diseases.
Clinical Development and Evaluation
This program is intended to address the limited availability of adjuvants that mimic those with a favorable clinical track record or show high potential in late pre-clinical testing.
Adjuvant Webinar Series
The NIAID Adjuvant Webinar Series is a monthly virtual presentation given on current research relating to vaccine adjuvants. Each month a new speaker is invited to share their findings with the adjuvant research community. The overall goals of the webinar series are to publicize recent developments in the adjuvant field and to encourage collaboration between adjuvant researchers. The webinar takes place on the fourth Tuesday of every month from 12:30 – 1:30 p.m. (ET), with a hiatus during the summer and winter.
If you are interested in being invited to attend the NIAID Adjuvant Webinar Series, email a request to Ari Joffe.
The series will resume in September after a summer break.